| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5538739 | NOVARTIS | Sustained release formulations of water soluble peptides |
Jul, 2013
(10 years ago) | |
|
US5538739 (Pediatric) | NOVARTIS | Sustained release formulations of water soluble peptides |
Jan, 2014
(10 years ago) | |
| US5639480 | NOVARTIS | Sustained release formulations of water soluble peptides |
Jun, 2014
(9 years ago) | |
| US5688530 | NOVARTIS | Sustained release formulations of water soluble peptides |
Nov, 2014
(9 years ago) | |
|
US5639480 (Pediatric) | NOVARTIS | Sustained release formulations of water soluble peptides |
Dec, 2014
(9 years ago) | |
|
US5688530 (Pediatric) | NOVARTIS | Sustained release formulations of water soluble peptides |
May, 2015
(8 years ago) | |
| US5922682 | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul, 2016
(7 years ago) | |
| US5922338 | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul, 2016
(7 years ago) | |
|
US5922338 (Pediatric) | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan, 2017
(7 years ago) | |
|
US5922682 (Pediatric) | NOVARTIS | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan, 2017
(7 years ago) | |
Sandostatin Lar is owned by Novartis.
Sandostatin Lar contains Octreotide Acetate.
Sandostatin Lar has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Sandostatin Lar are:
- US5538739
- US5538739*PED
- US5639480
- US5688530
- US5639480*PED
- US5688530*PED
- US5922682
- US5922338
- US5922338*PED
- US5922682*PED
Sandostatin Lar was authorised for market use on 25 November, 1998.
Sandostatin Lar is available in injectable;injection dosage forms.
Sandostatin Lar can be used as acromegaly.
The generics of Sandostatin Lar are possible to be released after 13 January, 2017.
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 25 November, 1998
Treatment: Acromegaly
Dosage: INJECTABLE;INJECTION
SANDOSTATIN LAR family patents
